2nd Circ. Asks How Expert Report Could Derail Pfizer Action
By Pete Brush ( May 26, 2015, 6:11 PM EDT) -- A Second Circuit panel wondered Tuesday how an extensively briefed securities fraud class action alleging Pfizer Inc. hid deadly risks associated with two painkillers could have been tossed on the eve of trial because of concerns over an economist's damages calculations, with two judges asking if less drastic measures would have sufficed....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.